Latest Case: Immunex Corp v. Sanofi-Aventis U.S. LLC (Drugs & Biotech)

In Gratuitously Attacking Marriage Equality, Clarence Thomas Accidentally Raised an Important Question About the Scope of Religious Liberty

MICHAEL C. DORF

Cornell law professor Michael C. Dorf comments on a statement by Justice Clarence Thomas (joined by Justice Samuel Alito) gratuitously expressing his hostility to the Court’s same-sex marriage decision in Obergefell v. Hodges and his sympathy for Kim Davis, a county clerk in Kentucky who refused to issue marriage licenses to same-sex couples even after the Supreme Court’s decision. Although Justice Thomas characterizes Davis and those like her as people who “refus[e] to alter their religious beliefs in the wake of prevailing orthodoxy,” Dorf points out that no one asked Davis to alter her religious beliefs. Rather, the lawsuit against her contends that she must provide services to the public in accordance with their constitutional rights, whatever her religious beliefs.

Read More

Immunex Corp v. Sanofi-Aventis U.S. LLC

Docket: 19-1749

Opinion Date: October 13, 2020

Judge: Sharon Prost

Areas of Law: Drugs & Biotech, Intellectual Property, Patents

Immunex’s 487 patent is directed to antibodies that bind to the human interleukin-4 receptor, the resulting inhibition of which is significant for treating various inflammatory disorders, such as arthritis, dermatitis, and asthma. Amid infringement litigation, Sanofi filed three inter partes review (IPR) petitions challenging claims 1–17 of the patent. Two were instituted. In one final written decision, the Board concluded that claims 1–17 were unpatentable as obvious over two prior references. Immunex appealed, contesting the construction of the claim term “human antibodies.” In the other IPR, involving a subset of the same claims, the Board did not invalidate the patents for reasons of inventorship. Sanofi contested the Board’s inventorship determination. In consolidated appeals, the Federal Circuit upheld the Board’s claim construction, affirming the invalidity decision, leaving valid no claims at issue in the inventorship appeal.